PMA increases M3 muscarinic receptor levels and decreases retinal cells proliferation through a change in the levels of cell-cycle regulatory proteins.

Autor: Braga LE; Departamento de Fisiologia e Farmacologia, Instituto Biomédico, UFF, Rua Hernani Pires de Mello, 101, Niterói CEP 24210-130, RJ, Brazil., Granja MG, da Silva GM, Giestal-de-Araujo E, dos Santos AA
Jazyk: angličtina
Zdroj: Neuroscience letters [Neurosci Lett] 2013 Aug 29; Vol. 550, pp. 29-34. Date of Electronic Publication: 2013 Jul 01.
DOI: 10.1016/j.neulet.2013.06.045
Abstrakt: Protein kinase C (PKC) pathway plays important roles in different phenomena in nervous system development. Our previous data demonstrated that phorbol 12-myristate 13-acetate (PMA) treatment, a PKC activator, for 48 h decreases retinal cells proliferation by a mechanism mediated by muscarinic receptor activation, involving a decrease in M1 receptors levels. The aim of this work was to analyze how PMA interferes in the levels of cell cycle control proteins p53, p21 and cyclin D1 and also to investigate its influence on M3 receptor levels. Our results show that PMA (50 ng/mL) produces a significant increase in p21 and p53 levels, decreases cyclin D1 levels, and also enhances M3 receptors levels in cell cultures. Evaluating the postnatal retinal tissue development until 30 days, we observed that tissue differentiation is accompanied by an increase in M3 and p21 levels. Based on our results we suggest that PMA treatment is promoting a change in muscarinic receptors expression mimicking the pattern observed during tissue differentiation, indicating that PMA is probably accelerating the cholinergic differentiation in rat retinal cell cultures.
(Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: